Get the Stockscreener App
70.29
0.41%
-0.29
After Hours:
70.29
Biomarin Pharmaceutical Inc stock is traded at $70.29, with a volume of 1.40M.
It is down -0.41% in the last 24 hours and down -22.94% over the past month.
See More
Previous Close:
$70.58
Open:
$70.58
24h Volume:
1.40M
Relative Volume:
0.82
Market Cap:
$13.13B
Revenue:
$2.59B
Net Income/Loss:
$256.59M
P/E Ratio:
91.44
EPS:
0.7687
Net Cash Flow:
$212.80M
1W Performance:
+1.68%
1M Performance:
-22.94%
6M Performance:
-19.52%
1Y Performance:
-20.56%
1-Day Range:
$69.91
$71.23
1-Week Range:
$67.75
$71.23
52-Week Range:
$67.75
$99.56
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Name
Biomarin Pharmaceutical Inc
Sector
Industry
Phone
(415) 506-6700
Address
105 DIGITAL DRIVE, NOVATO, CA
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-15-23 | Initiated | Wells Fargo | Overweight |
| Oct-23-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Sep-28-23 | Initiated | Raymond James | Mkt Perform |
| Sep-18-23 | Initiated | UBS | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| Jul-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Feb-22-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-21-23 | Initiated | Citigroup | Neutral |
| Jan-30-23 | Initiated | BMO Capital Markets | Market Perform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Oct-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| Apr-25-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-22-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-09-21 | Upgrade | Stifel | Hold → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-04-21 | Resumed | Guggenheim | Buy |
| Mar-01-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Aug-20-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-19-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-19-20 | Downgrade | Stifel | Buy → Hold |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-06-20 | Reiterated | Citigroup | Buy |
| Jan-28-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-27-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-24-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-27-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-23-19 | Resumed | Citigroup | Buy |
| Apr-09-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-18 | Reiterated | Stifel | Buy |
| Aug-03-18 | Reiterated | Stifel | Buy |
View All
Biomarin Pharmaceutical Inc Stock (BMRN) Latest News
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term - Yahoo Finance
High Growth Tech Stocks To Watch For Future Potential - Simply Wall St
Novo Holdings A S Purchases 40,000 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Susquehanna Fundamental Investments LLC Invests $5.63 Million in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
ProShare Advisors LLC Has $1.70 Million Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Wall Street SWOT: BioMarin stock poised for growth amid rare disease focus - Investing.com
Deerfield Management Company L.P. Series C Invests $809,000 in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
DeepCurrents Investment Group LLC Sells 17,961 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish - Benzinga
BIIB: 3 Biotech Stocks Wall Street Predicts Will Skyrocket - StockNews.com
BioMarin’s Voxzogo stock outlook intact as competition rises, says Goldman Sachs - Investing.com
BioMarin’s Voxzogo stock outlook intact as competition rises, says Goldman Sachs - Investing.com India
Troluce Capital Advisors LLC Takes Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin stock touches 52-week low at $68.8 amid market challenges - Investing.com Australia
Layoff Tracker: Bluebird Bio to Cut 25% of Workforce and More News - BioSpace
Examining the Potential Price Growth of Biomarin Pharmaceutical Inc. (BMRN) - Knox Daily
Biomarin Pharmaceutical Options Trading: A Deep Dive into Market Sentiment - Benzinga
BioMarin Pharmaceutical reaffirms long-term outlook - MSN
BioMarin Pharmaceutical (NASDAQ:BMRN) Hits New 12-Month Low at $68.73 - Defense World
BioMarin Pharmaceutical (NASDAQ:BMRN) Reaches New 52-Week Low at $68.73 - MarketBeat
BioMarin stock touches 52-week low at $68.8 amid market challenges - Investing.com
BioMarin stock touches 52-week low at $68.8 amid market challenges - Investing.com UK
Australis mortgages 15 Chilean salmon farms to BioMar, Vitapro - Undercurrent News
BioMarin Pharmaceutical Projects Strong Growth Through 2034 - TipRanks
Biomarin Pharmaceutical Inc Reaffirming Its Long-Term Financial Guidance And Outlook That It Presented During Investor Day - XM
BioMarin Pharmaceutical (NASDAQ:BMRN) Issues FY 2024 Earnings Guidance - Defense World
BioMarin Pharmaceutical (NASDAQ:BMRN) Issues FY 2024 Earnings Guidance - MarketBeat
Poor planning, patient reluctance, and payer problems hurting gene therapy space - BioProcess Insider
Renaissance Technologies LLC Decreases Stock Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
New 4-Star Stocks - Morningstar
Daily Market Movement: Biomarin Pharmaceutical Inc. (BMRN) Sees a -1.01 Decrease, Closing at 70.69 - The Dwinnex
BioMar sees farm partnerships, tech as future of shrimp feed M&A - Undercurrent News
Avoro Capital Advisors LLC Increases Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Canada Pension Plan Investment Board Has $19.80 Million Stock Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Defense World
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio? - Benzinga
Ameritas Investment Partners Inc. Makes New Investment in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) Seems To Use Debt Rather Sparingly - Simply Wall St
BioMarin (BMRN): Strong Results and ROCTAVIAN Progress Make It a Mid-Cap Growth Gem - Insider Monkey
BioMarin (BMRN): Strong Results and ROCTAVIAN Progress Make It a Mid-Cap Growth Gem - Yahoo Finance
20,167 Shares in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Bought by Federated Hermes Inc. - MarketBeat
Simplify Asset Management Inc. Takes $417,000 Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Defense World
Amalgamated Bank Grows Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Expected to Earn Q1 2025 Earnings of $0.59 Per Share - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Bought by Meiji Yasuda Life Insurance Co - Defense World
Mutual of America Capital Management LLC Purchases Shares of 108,713 BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Defense World
Citi maintains Neutral on BioMarin with $93 target - Investing.com India
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Bought by E Fund Management Co. Ltd. - MarketBeat
Citi maintains Neutral on BioMarin with $93 target By Investing.com - Investing.com Canada
BioMarin Pharmaceutical (NASDAQ:BMRN) PT Lowered to $90.00 - Defense World
Citi maintains Neutral on BioMarin with $93 target - Investing.com
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Short Interest Update - Defense World
Biomarin Pharmaceutical Inc Stock (BMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):